Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Rudra Pratap Singh Rajput
Shri Rawatpura Sarkar Institute of Pharmacy, India
Title : Formulation, characterization and evaluation: Micellar loaded complex of Cuminum Cyminum to treat causing disease of COVID 19 (Respiratory infection)


Coronaviruses are a family of viruses that can cause illnesses such as the common cold, Fever, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Cancer, Asthma etc. Respiratory infection (RTI) is a viral spreading disease and it transmits from individual to individual, particularly in youngsters and aged peoples. The treatments are available but have so many limitations. To treat RTI, the phyto-constituent antibacterial drug cuminaldehyde (Cuminum Cyminum L.) was selected but it exhibits low bioavailability, poor water-solubility and is rapidly eliminated from the body. To overcome these issues, novel drug delivery (nanoparticle) based micellar loaded complex approach was adopted. In this study, the micellar (CM) was prepared by mixing of cuminaldehyde and soya lecithin using anti-solvent precipitation technique and further the micellar loaded complex (CMLC) was prepared by loading of micellar (CM) in aqueous solution of chitosan. The physical compatibility studies by DSC and FT-IR, demonstrated the confirmation of CMLC with soya lecithin and chitosan. The optimized CMLC and CM were irregular particle shapes and crystalline structures, with a mean particle size of 279.10±0.02 nm, 296.24±0.10 nm and zeta potential of -8.18 mV, -8.77 mV, respectively. The % entrapment efficiency and % drug loading of CMLC (72.13±0.26 %, 06.46±0.01 %) and CM (89.09±0.20%, 08.05±0.19 %) was found efficiently. The in vitro release rate of CM (88.09±0.41 %) was slower than CMLC (89.02±0.06 %) in pH 7.4 phosphate buffer up to 24 h by diffusion process (Korsmeyer Peppas model). Furthermore, CMLC has shown the potent in vitro antioxidant activity, susceptible antibacterial activity and significant anti-inflammatory activity as compared to CM against stress, microbial infection (S. aureus and E. coli) and inflammation which were causable reason for the respiratory infections. CLMC has shown the significant bioavailability and more efficient hematological parameters value on rabbit blood against the incubation of bacterial organism. CLMC may have the effective potential to treat causing disease of COVID 19 i.e. RTI.


Dr. Rudra studied Ph.D degree in 2018 at JSSAHER, Mysuru, Karnataka, India and post graduated as M.Pharm in Pharmaceutics specialization in 2014 from Pune University, Pune (MH). He, then joined in academics at Shri Rawatpura Sarkar Institute of Pharmacy (SRIP), Kumhari, Durg, Chhattisgarh. He has more than 8 years of teaching and research experience in Novel drug delivery systems, nano-technology as so on. He has published more than 33 review and research papers in SCI(E) and Scopus indexed journals. He, also received number of awards at National and International platforms.